>
Switch to:

Intec Parent PS Ratio

: (As of Today)
View and export this data going back to 1996. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Intec Parent's share price is $9.63. Intec Parent's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 was $0.00. Hence, Intec Parent's PS Ratio for today is .

The historical rank and industry rank for Intec Parent's PS Ratio or its related term are showing as below:

Intec Parent's Revenue per Sharefor the three months ended in Mar. 2021 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 was $0.00.

Back to Basics: PS Ratio


Intec Parent PS Ratio Historical Data

The historical data trend for Intec Parent's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intec Parent Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PS Ratio
Premium Member Only Premium Member Only Premium Member Only - - - - -

Intec Parent Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Intec Parent's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Intec Parent PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Intec Parent's PS Ratio distribution charts can be found below:

* The bar in red indicates where Intec Parent's PS Ratio falls into.



Intec Parent PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Intec Parent's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=9.63/0
=

Intec Parent's Share Price of today is $9.63.
Intec Parent's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Intec Parent  (NAS:NTEC) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Intec Parent PS Ratio Related Terms

Thank you for viewing the detailed overview of Intec Parent's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Intec Parent Business Description

Intec Parent logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
N/A
Address
12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512
Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.
Executives
Linscott Walt Addison officer: Chief Business Officer 1860 MONTREAL ROAD TUCKER GA 30084
Sassi Nir officer: Chief Financial Officer 3 ELUL STREET, APT. 6 MODIIN L3 7176397
Navon Nadav officer: Chief Operating Officer 18 LEA IMENU STREET MODIIN L3 7177945
Maddaluna Anthony J director PFIZER INC. ATTN CORPORATE SECRETARY 235 RAST 42ND STREET NEW YORK NY 10017
Hayes William B director 231 MAPLE AVENUE BURLINGTON NC 27215
Pomerantz Roger director 711 HARVEST HILL ROAD CHALFONT PA 18914
Karah Hila director 9 HALAMISH STREET CAESAREA INDUSTRIAL PARK CAESAREA L3 38900
Kozarich John W director 10275 SCIENCE CENTER DR SAN DIEGO CA 92121
Meckler Jeffrey A director, officer: Chief Executive Officer 740 BROADWAY 9TH FLOOR NEW YORK NY 10003
Gendreau R Michael officer: Chief Medical Officer 4350 EXECUTIVE DRIVE SUITE 325 SAN DIEGO CA 92121
Oren Dan 10 percent owner 1 DEXCEL STREET OR AKIVA L3 30600000
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET OR AKIVA L3 3060000
Bianco Gil director 7 HAORANIM STREET BAZRA L3 60944
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)